SOPHiA DDM for Multimodal

SOPHiA DDM™ for Multimodal is a data-driven oncology research platform developed by SOPHiA GENETICS that breaks down data silos by unifying genomic, imaging, clinical, and biological data within a single environment. Designed for researchers, clinicians, and biopharma teams seeking to explore new frontiers in cancer biology and disease, the platform harnesses powerful AI and machine learning algorithms to generate entirely novel insights and accelerate the adoption of precision medicine.

At the core of the platform is SOPHiA CarePath®, which serves as the integrated environment for multimodal data harmonization, visualization, patient cohorting, and predictive analytics. The SOPHiA DDM™ Multimodal harmonization engine standardizes data from different models and multiple centers, enabling meaningful research hypothesis generation and collaboration across institutions.

Core Capabilities

• Comprehensive data integration: Multimodal healthcare data — including genomic, radiomic, clinical, and biological data — are securely uploaded through a meticulous ETL process from various sources and multiple centers into SOPHiA CarePath®, ensuring accurate, consistent, and high-quality data integration and storage.
• AI-powered harmonization: The SOPHiA DDM™ multimodal harmonization engine integrates data from different data models and standardizes it for visualization, cohorting, and analysis. Machine learning models are developed in the SOPHiA DDM™ Multimodal Factory to reliably identify predictive signals.
• Predictive model development: Advanced AI algorithms are harnessed to uncover actionable insights and drive new discoveries, including the identification of trends in disease relapse, treatment response, and toxicity across oncology indications.
• Global collective intelligence: The platform supports participation in multicenter research studies, enabling patient cohorting and multimodal data visualization across a global network of leading healthcare institutions.

Workflow Steps

1. Login and data upload
2. Data visualization
3. 3D segmentation
4. Feature extraction
5. Analysis and reporting

Key Platform Functions

• Visualization: SOPHiA CarePath® enables the visualization of longitudinal patient data, including routine imaging. This capability is demonstrated through the DEEP-Lung-IV international observational study, which combines real-world clinical, biological, genomic, and radiomic data to identify predictive treatment response signatures in stage IV non-small cell lung cancer (NSCLC).
• Cohorting: Real-world data is standardized and harmonized, with cohorting capabilities leveraged to generate novel research hypotheses, as demonstrated in the DEEP-Lung-IV study.
• Prediction: In collaboration with UroCCR, the French Kidney Cancer Research Network, SOPHiA GENETICS developed a machine learning model for predicting kidney cancer recurrence. The resulting UroPredict calculator predicts the probability of disease-free survival and assigns patients to a recurrence risk group.

Digital Twins

• SOPHiA DDM™ Digital Twins harnesses a highly curated clinico-genomics dataset with real-world outcomes to support a more informed patient health journey through comparison with similar profiles.
• Enhances the clinical utility of MSK Solutions powered by SOPHiA DDM™ by providing insights into progression-free survival, overall survival, and clinical response at 3 months.

Multimodal Research Projects

• DEEP-Lung-IV: An international observational real-world multimodal study uncovering signals linked to outcomes in stage IV NSCLC.
• TRIDENT: A predictive model developed for the TRIDENT post hoc analysis of AstraZeneca's POSEIDON trial in metastatic NSCLC.
• UroPredict: A collaboration with the French Kidney Cancer Research Network to analyze real-world data and predict kidney cancer recurrence.

SOPHiA UNITY Community

• SOPHiA UNITY is a global network of leading healthcare institutions advancing oncology research through collaboration.
• This data-driven community harnesses collective intelligence to draw deeper insights from multimodal data and enhance cancer care.

SOPHiA GENETICS products, including SOPHiA DDM™ for Multimodal, are intended for Research Use Only unless specified otherwise. Certain SOPHiA DDM™ Dx solutions are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and select other regions. Availability and regulatory clearance may vary by country and indication.